This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Academic Highlights

The Role of Norepinephrine in the Treatment of Depression

 

Published: September 30, 1999

This CME activity is expired. For more CME activities, visit CMEInstitute.com.
Find more articles on this and other psychiatry and CNS topics:
The Journal of Clinical Psychiatry
The Primary Care Companion for CNS Disorders


Article Abstract

Despite recent strides in treatment, depression remains a common, costly, and often deadly disease, Dr. Charles B. Nemeroff stated. More than 1.2 million persons are diagnosed with an affective disorder in the United States each year, an incidence of approximately 5% to 10%, and depression is more prevalent than arthritis, diabetes, or heart disease. Depression is also a costly disease: in 1990 it was estimated that in the United States alone the cost of depression approached $44 billion, including direct costs for medication, physician services, etc., as well as indirect costs such as increased morbidity, excessive absenteeism, and reduced productivity. Depression also has a high mortality: up to 15% of severely depressed patients will ultimately commit suicide.

Volume: 60

Quick Links: Depression (MDD)

Continue Reading…

Subscribe to read the entire article

$40.00

Buy this Article as a PDF

References

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Original Research

Effect of Zuranolone on Concurrent Anxiety and Insomnia Symptoms in Women With Postpartum Depression

Zuranolone was associated with improvements in depressive and anxiety symptoms and was beneficial for insomnia and patient-perceived...

Read More...